首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Differential In Vivo Activities of Anidulafungin Caspofungin and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations
【2h】

Differential In Vivo Activities of Anidulafungin Caspofungin and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations

机译:AnidulafunginCaspofungin和Micafungin对带有和不带有FKS抗性突变的光滑念珠菌分离株的体内差异活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We recently observed that the micafungin MICs for some Candida glabrata fks hot spot mutant isolates are less elevated than those for the other echinocandins, suggesting that the efficacy of micafungin may be differentially dependent on such mutations. Three clinical C. glabrata isolates with or without (S3) fks hot spot mutations R83 (Fks2p-S663F) and RR24 (Fks1p-S629P) and low, medium, and high echinocandin MICs, respectively, were evaluated to assess the in vivo efficacy in an immunocompetent mouse model using three doses of each echinocandin. Drug concentrations were determined in plasma and kidneys by high-performance liquid chromatography (HPLC). A pharmacokinetic-pharmacodynamic mathematical model was used to define the area under the concentration-time curve (AUC) that produced half- and near-maximal activity. Micafungin was equally efficacious against the S3 and R83 isolates. The estimates for the AUCs of each echinocandin that induced half-maximal effect (E50s) were 194.2 and 53.99 mg · h/liter, respectively. In contrast, the maximum effect (Emax) for caspofungin was higher against S3 than R83, but the estimates for E50 were similar (187.1 and 203.5 mg · h/liter, respectively). Anidulafungin failed to induce a ≥1-log reduction for any of the isolates (AUC range, 139 to 557 mg · h/liter). None of the echinocandins were efficacious in mice challenged with the RR24 isolate despite lower virulence (reduced maximal growth, prolonged lag phase, and lower kidney burden). The AUC associated with half-maximal effect was higher than the average human exposure for all drug-dose-bug combinations except micafungin and the R83 isolate. In conclusion, differences in micafungin MICs are associated with differential antifungal activities in the animal model. This study may have implications for clinical practice and echinocandin breakpoint determination, and further studies are warranted.
机译:我们最近观察到,对于某些光滑念珠菌fks热点突变株,米卡芬净MIC的升高低于其他棘球chin素的MIC,这表明米卡芬净的功效可能与此类突变有所不同。分别评估了三个带有或不带有(S3)fks热点突变R83(Fks2p-S663F)和RR24(Fks1p-S629P)和低,中和高棘皮棘菌素MIC的临床光滑念珠菌。一种免疫活性的小鼠模型,使用每种剂量的棘皮菌素三剂。通过高效液相色谱(HPLC)测定血浆和肾脏中的药物浓度。使用药代动力学-药效学数学模型定义浓度-时间曲线(AUC)下产生一半和接近最大活性的面积。米卡芬净对S3和R83分离株同样有效。每种棘皮生物素引起的半数最大效应(E50)的AUC估计分别为194.2和53.99 mg·h /升。相比之下,卡泊芬净对S3的最大作用(Emax)高于R83,但对E50的估计却相似(分别为187.1和203.5 mg·h /升)。对于任何分离株(AUC范围为139至557 mg·h /升),阿尼芬净均未能引起≥1-log的降低。尽管毒性较低(尽管最大生长力降低,延迟期延长和肾脏负担降低),但在用RR24分离物攻击的小鼠中,棘轮and蛋白均无效。除米卡芬净和R83分离物外,所有药物剂量-虫子组合的半数最大效应相关的AUC高于人类平均暴露量。总之,米卡芬净MICs的差异与动物模型中不同的抗真菌活性有关。这项研究可能对临床实践和棘皮菌素断点的确定有影响,因此有必要做进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号